Vaniqa, a hair growth retardant, is indicated to reduce unwanted facial hair in women. Vaniqa (eflornithine HCl; Allergan) Cream 13.9% is currently unavailable due to a shortage of active ingredient, ...

Vaniqa is an Rx dermatological cream that reduces “unwanted facial hair” in women. It’s a “cosmeceutical” brand that falls somewhere between the dermatologist’s office and your local Sephora, and its ...

Eflornithine 13.9% (Vaniqa) cream is FDA-approved to reduce growth of unwanted facial hair in women. A randomized trial of 33 women aged 22-65 years evaluated the efficacy of eflornithine use in ...

Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher" or "the Company") today announced it has strengthened its Canadian dermatology portfolio by acquiring the Canadian rights to Vaniqa ® and ...

VANIQA (R) (Eflornithine 13.9% hydrochloride) cream, applied twice-daily on affected area, can help women by slowing the growth of their unwanted facial hair. VANIQA (R) is the first prescription ...

CARLSBAD, Calif.--(BUSINESS WIRE)--June 28, 2004--SkinMedica(R) Inc., a specialty pharmaceutical company developing and commercializing dermatology products, announced today that it is the winning ...

HOUSTON RediClinic, which operates more than 20 clinics in H-E-B grocery stores in Houston and Austin, has expanded its menu of services with the addition of prescription medications Vaniqa and Lustra ...

MISSISSAUGA, ON, June 2, 2015 /CNW/ - Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX: CPH) ("Cipher" or "the Company") today announced the appointments of Louise Blythe as Vice President, Regulatory ...